Form 4: Elicio Therapeutics CEO Acquires Stock Options
SEC Form 4 Filing
Robert Connelly, CEO of Elicio Therapeutics, reports the acquisition of stock options.
Summary
- Robert Connelly, the CEO, President, and Director of Elicio Therapeutics, Inc. acquired stock options on February 3, 2025.
- The transaction involved the acquisition of 121,600 stock options with an exercise price of $8.92.
- These options vest over time, with 25% vesting on February 3, 2026, and the remainder vesting monthly over the subsequent three years, contingent upon continued service.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing related to executive compensation, which is neither particularly positive nor negative. It's a neutral event.
Positives
- The acquisition of stock options by the CEO could align his interests with those of the shareholders, incentivizing him to improve the company's performance.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Executive compensation packages, including stock options, are common in the biotech industry to attract and retain talent.
- Vesting schedules, such as the one described (25% after one year, then monthly over three years), are typical for stock option grants.
- Comparing the exercise price and the number of options granted to similar companies in the biotech sector would provide a benchmark for assessing the competitiveness of the compensation package.
Stakeholder Impact
- The stock option grant could potentially incentivize the CEO to increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of stock option acquisition |
| 02/03/2026 | First vesting date for 25% of the stock options |
| 02/04/2025 | Date of Form 4 signature |
| 02/03/2035 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.